gms | German Medical Science

68th Annual Meeting of the German Society of Neurosurgery (DGNC)
7th Joint Meeting with the British Neurosurgical Society (SBNS)

German Society of Neurosurgery (DGNC)

14 - 17 May 2017, Magdeburg

The metalloprotease ADAM8 mediates brain metastasis formation by regulating transendothelial migration

Meeting Abstract

  • Catharina Conrad - Klinik für Anästhesiologie, operative Intensivmedizin und Schmerztherapie, Albert-Schweitzer-Campus, Münster, Deutschland
  • Malena Götte - Klinik für Neurochirurgie, Universität Marburg, Marburg, Deutschland
  • Uwe Schlomann - Klinik für Neurochirurgie, Universität Marburg, Marburg, Deutschland
  • Barbara Carl - Klinik für Neurochirurgie, Universität Marburg, Marburg, Deutschland
  • Christopher Nimsky - Klinik für Neurochirurgie, Universität Marburg, Marburg, Deutschland
  • Jörg-Walter Bartsch - Klinik für Neurochirurgie, Universität Marburg, Marburg, Deutschland

Deutsche Gesellschaft für Neurochirurgie. Society of British Neurological Surgeons. 68. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), 7. Joint Meeting mit der Society of British Neurological Surgeons (SBNS). Magdeburg, 14.-17.05.2017. Düsseldorf: German Medical Science GMS Publishing House; 2017. DocP 102

doi: 10.3205/17dgnc665, urn:nbn:de:0183-17dgnc6659

Published: June 9, 2017

© 2017 Conrad et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License. See license information at http://creativecommons.org/licenses/by/4.0/.


Outline

Text

Objective: Brain metastases outnumber primary neoplasms ten-fold, and are associated with a poor prognosis. Patients with metastatic, triple negative breast cancers are at high risk (25-46%) of developing brain metastases at some point in the course of their disease. Recently we demonstrated that high ADAM8 expression in breast tumors lead to increased numbers of circulating tumor cells and a higher frequency of brain metastasis in mouse tumor models. Thus, we evaluated the mechanistic role of ADAM8, a metalloprotease-disintegrin, in facilitating trans-endothelial migration and in the formation of brain metastases.

Methods: Brain metastases were analysed using immunohistochemistry for ADAM8. To model brain metastasis of breast cancer cells, stable shRNA ADAM8 knock-down clones of the breast cancer cell line MDA-MB-231 (shA8) and control (shCtrl) cells were generated and subjected to functional assays assessing migration, invasion, and transmigration through a Blood Brain Barrier model consisting of endothelial cells and astrocytes. In addition, MMP expression was analysed in MDA-MB-231 shCtrl and shA8 cells by qPCR. Furthermore, comparative phospho-kinase arrays were utilized. Cell model data were correlated to brain metastases from primary breast tumors.

Results: A significant increase in ADAM8 expression was identified in 34% of primary site tumors, and was found to be 2-fold higher in brain metastases of different origins, including breast cancer. In transendothelial migration assays, MDA-MB-231 ADAM8 knock-down cells showed a reduced endothelial adhesion as well as a reduced transmigratory capacity both in serum-induced transmigration and in transmigration triggered by the chemokine SDF-1, a mediator of metastasis. This was further supported by the blood-brain barrier in vitro model as well as in matrigel invasion assays. ADAM8 knockdown caused reduced ERK1/2 and CREB phosphorylation and affected expression levels of MMP9 specifically. We demonstrated that in the course of transendothelial migration, the P-selectin glycoprotein ligand, a membrane protein important in leukocyte extravasation, is shed by ADAM8.

Conclusion: Our results suggest that ADAM8 is an important mediator for brain metastasis of breast cancer by affecting transendothelial migration and may offer an attractive target for therapeutic interventions.